Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]) for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 4 May 2026: Trial started, NCT07611110
  2. 28 May 2026: Trial registered, NCT07611110

The trials

NCT07611110: AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

State
Under way
Phase
Phase 3
People
670 planned
Started
4 May 2026
Primary completion
4 Jun 2029
Arms
Arm A
Results
None posted
  1. 4 May 2026: Trial started
  2. 28 May 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.